Trial Profile
A retrospective study evaluating effect of dolutegravir in combination with Nucleoside Reverse Transcriptase Inhibitors (NRTIs) on people living with HIV who had pre-existing NRTI mutations
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Oct 2018
Price :
$35
*
At a glance
- Drugs Dolutegravir (Primary)
- Indications HIV infections
- Focus Therapeutic Use
- 12 Oct 2018 New trial record